Document:

<Page>

                                                                   Exhibit 10.1

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                       STRENGTH RESEARCH LICENSE AGREEMENT

This AGREEMENT (the "Agreement") is made as of the 5TH day of September 2003
(the "Effective Date"), by and between Genaissance Pharmaceuticals, Inc., a
Delaware Corporation with its principal place of business at Five Science Park,
New Haven, CT 06511 ("Genaissance"), and AstraZeneca UK Limited, a United
Kingdom company with its principal place of business at 15 Stanhope Gate, London
W1K 1LN, United Kingdom ("AstraZeneca").

                                    RECITALS

     WHEREAS, Genaissance has conducted the STRENGTH Trial (as hereinafter
defined) to investigate the relationship between genetic variation and variable
response to certain Statins, (as hereinafter defined), and has discovered
associations between various genes and phenotypic responses to certain Statins
(Genaissance SR Gene Associations, as further defined below); and

     WHEREAS, Genaissance has developed a proprietary suite of programs that
assemble, process, search, manipulate and analyze genetic and clinical data to
facilitate finding correlations between genomic variation and drug response (the
DECOGEN(R) Informatics Platform, as further defined below),

     WHEREAS, AstraZeneca is interested in obtaining a limited research license
to use the DECOGEN(R) Informatics Platform, the Genaissance SR Gene
Associations, and their underlying clinical and genetic data from the STRENGTH
trial, to investigate the genetic basis of variable response to Statins; and

     WHEREAS, Genaissance is willing to grant AstraZeneca this limited license
upon the terms and conditions set forth below.

     NOW THEREFORE, in consideration of the premises and of the covenants herein
contained, the parties hereto mutually agree as follows:

                                    ARTICLE 1
                                   DEFINITIONS

     1.1 "AFFILIATE" shall mean any corporation, firm, partnership or other
legal entity that, directly or indirectly, controls, is controlled by, or is
under common control with a Party. For purposes of this definition, control
shall mean the direct or indirect ownership of more than fifty percent (50%) of
(i) the stock shares entitled to vote for the election of directors or (ii)
ownership interest of any such corporation, firm, partnership or other legal
entity.

     1.2 "ASSOCIATION SUMMARY TABLE" shall mean the table in EXHIBIT A that
lists the Candidate Genes and Clinical Phenotypes evaluated in the STRENGTH
Trial, as well as Genaissance SR Associations discovered by Genaissance as of
the Effective Date, or any updates thereto that are made prior to the
Installation Date.

     1.3 "ASTRAZENECA KNOW-HOW" shall mean any and all proprietary data,
information, know-how, inventions, trade secrets, copyrights, regulatory
submissions or other intellectual

<Page>

property of any kind, other than Patent Rights, owned or controlled by
AstraZeneca, as of the Effective Date or during the Term.

     1.4 "ASTRAZENECA PATENT RIGHTS" shall mean Patent Rights owned or
controlled by AstraZeneca or its Affiliates, including any Patent Rights
claiming Foreground IP.

     1.5 "ASTRAZENECA PROPRIETARY DATABASE" shall mean a database that is
installed on the Computer that is accessible by the DECOGEN Informatics System
and that contains (a) clinical data and genetic data for patients from
AstraZeneca clinical trials and (b) data generated from the Research Study.

     1.6 "ASTRAZENECA SR CORRELATION" shall mean any correlation identified by
AstraZeneca or its Affiliates during the Research Study that (a) meets a
statistical significance level defined by AstraZeneca in the Research Study
Plan, (b) is between a specific Genetic Marker or Genetic Markers in a specific
Candidate Gene or Candidate Genes and response to one or more Statins as
measured by a specific Clinical Phenotype or Clinical Phenotypes, wherein the
combination of the specific Candidate Gene or Candidate Genes and Clinical
Phenotype or Clinical Phenotypes and Statin or Statins is not part of a
Genaissance SR Association.

     1.7 "CANDIDATE GENE" shall mean a gene evaluated by Genaissance in the
STRENGTH Trial.

     1.8 "CLASS-WIDE STATIN EFFECT" shall mean an individual's response
(efficacy or adverse drug reaction) to any Statin in the Statin class (Crestor,
Lipitor, Pravachol and Zocor), which shall include a response to each of the
four statins (Crestor, Lipitor, Pravachol and Zocor), wherein the p-value for
the correlation to at least [**] the [**] is not more than [**] with correction
for [**] as defined by AstraZeneca in the Research Study Plan AND the p-value
for the correlation to the [**] is not more than [**] with correction for [**]
as defined by AstraZeneca in the Research Study Plan. A correlation to a
class-wide effect shall NOT include a response to each of the four statins
(Crestor, Lipitor, Pravachol and Zocor), wherein the p-value for the correlation
to at least [**] the [**] is more than [**] with correction for [**] as defined
by AstraZeneca in the Research Study Plan AND the p-value for the correlation to
the [**] is more than [**] with correction for [**] as defined by AstraZeneca in
the Research Study Plan, NEITHER shall a correlation to a class-wide effect
include a response to each of the four statins (Crestor, Lipitor, Pravachol and
Zocor), wherein the p-value for the correlation to at least [**] the [**] is
more than [**] with correction for [**] as defined by AstraZeneca in the
Research Study Plan OR the p-value for the correlation to the [**] is more than
[**] with correction for [**] as defined by AstraZeneca in the Research Study
Plan.

     1.9 "CLASS-WIDE STATIN THERANOSTIC PRODUCT" shall mean any product or
service that (a) is intended for use in the prognosis of an individual's
response (either efficacy or adverse drug reaction) to any Statin and (b)
detects directly or indirectly (i) one (1) or more Genetic Markers correlated
with a Class-Wide Statin Effect (as defined in 1.8) or (ii) one (1) or more
Surrogate Markers of such Markers.

<Page>

     1.10   "CLINICAL DATA DICTIONARY" shall mean the definitions for the
Clinical Phenotype abbreviations used in the STRENGTH Database and in the
Association Summary Table in EXHIBIT A.

     1.11   "CLINICAL PHENOTYPE" shall mean an efficacy endpoint or an adverse
event, or both, following the administration of a Statin, as selected from the
efficacy endpoints and adverse events listed in the Association Summary Table in
EXHIBIT A.

     1.12   "COMPUTER" shall mean a computer owned by Genaissance that is
installed at the AstraZeneca location identified in EXHIBIT B and that contains
the Genaissance Background IP.

     1.13   "[**]-SPECIFIC CORRELATION" shall mean a correlation identified by
AstraZeneca or its Affilates during the Research Study that (a) meets a
statistical significance level defined by AstraZeneca in the Research Study
Plan, (b) is between one or more Genetic Markers in one or more specific
Candidate Genes and whose response as measured by a specific Clinical Phenotype,
and (c) does NOT meet the criteria for a Class-wide Statin Effect as defined in
Section 1.8.

     1.14   "DECOGEN(R) INFORMATICS PLATFORM" shall mean software and components
thereof and any associated documentation, whether existing on the Effective Date
or developed by Genaissance during the Term, which is owned or controlled by, or
licensed (with the right to sublicense) to Genaissance, and which includes the
DecoGen Browser software and the DecoGen DataManager software, with the features
of these software products being further described in Exhibit C hereto. The
DecoGen Informatics Platform shall not include any Third Party software that
AstraZeneca has independently of Genaissance licensed from a Third Party.

     1.15   "EXTENDED TERM" shall mean the one year period after the end of the
Initial Term, provided that AstraZeneca has paid the Term Extension Fee set
forth in Section 4.2.

     1.16   "FOREGROUND IP" shall mean all AstraZeneca SR Correlations,
[**]-Specific Correlations and any other intellectual property arising from the
Research Study, but excludes correlations between a Candidate Gene and Clinical
Phenotype and Statin present in the STRENGTH Database at the installation date.

     1.17   "GENAISSANCE BACKGROUND IP" shall mean (a) the STRENGTH Database and
its contents as of the Installation Date or during the Term, specifically
including all Genaissance SR Associations, and (b) the DECOGEN Informatics
Platform as of the Installation Date or during the Term.

     1.18   "GENAISSANCE KNOW-HOW" shall mean any and all proprietary data,
information, know-how, inventions, trade secrets, copyrights, regulatory
submissions or other intellectual property of any kind, other than Patent
Rights, owned solely by Genaissance, as of the Effective Date or during the
Term.

     1.19   "GENAISSANCE PATENT RIGHTS" shall mean all Patent Rights owned or
controlled by Genaissance, including Patent Rights claiming Background IP.

<Page>

     1.20   "GENAISSANCE SR ASSOCIATION" shall mean any statistically
significant association (p LESS THAN OR EQUAL TO [**], corrected for [**]) that
is (i) between a specific Genetic Marker in a specific Candidate Gene and
response to one or more Statins as measured by a specific Clinical Phenotype and
(ii) present in the STRENGTH Database on the Installation Date.

     1.21   "GENETIC MARKER" shall mean any Polymorphism or Haplotype in a
Candidate Gene.

     1.22   "HAPLOTYPE" shall mean an ordered combination of two (2) or more
Polymorphisms present in a Candidate Gene on a single chromosome.

     1.23   "INITIAL TERM" shall mean the period commencing on the Effective
Date and ending one year from the Effective Date.

     1.24   "INSTALLATION DATE" shall mean the date the Computer is received by
AstraZeneca.

     1.25   "NON-[**] STATIN-SPECIFIC THERANOSTIC PRODUCT" shall mean any
product or service that (a) is intended for use in the prognosis of an
individual's response (efficacy or adverse drug reaction) to a specific Statin
other than [**] and (b) detects directly or indirectly (i) one (1) or more
Genetic Markers correlated with response to a specific Statin other than [**] or
(ii) one (1) or more Surrogate Markers of such Genetic Markers.

     1.26   "PARTY" shall mean AstraZeneca and its Affiliates or Genaissance;
"PARTIES" means AstraZeneca and its Affiliates and Genaissance.

     1.27   "PATENT RIGHTS" shall mean patents or patent applications as
described hereinafter which are owned or controlled (with the right to grant
licenses) by a Party to this agreement. More particularly, Patent Rights include
(i) any United States or foreign patent application, (ii) any United States
patent or foreign patent issuing from such patent application and (iii) any
continuation, continuation-in-part (to the extent the claims in such
continuation-in-part application are directed to subject matter specifically
described in such prior patent application), divisional, reissue,
re-examination, renewal, substitution, addition, extension, supplementary
protection certificate or foreign counterpart thereof of any of the foregoing.

     1.28   "POLYMORPHISM" shall mean any alternative sequence found at a given
position in a Candidate Gene within a population including, but not limited to:
(a) single nucleotide polymorphisms ("SNPs"); (b) insertions and deletions of
one or more nucleotides; (c) repeats of one or more nucleotides; and (d)
restriction fragment length polymorphisms.

     1.29   "RESEARCH STUDY" shall mean the study designed and performed during
the Initial Term by AstraZeneca which uses the data in the STRENGTH Database
solely to investigate the genetic basis of variable response to Statins,
PROVIDED, THAT, AstraZeneca shall have sole discretion whether to conduct the
Research Study. For the avoidance of doubt, the Research Study shall be a study
that is carried out as a consequence of information contained in the STRENGTH
Database, i.e. it is not any research study investigating the genetic basis of
variable response to Statins that AstraZeneca may carry out during the Initial
Term and/or Extended Term without using information in the STRENGTH Database.

<Page>

     1.30   "RESEARCH STUDY PLAN" shall mean the plan for the Research Study set
forth on EXHIBIT D to this Agreement.

     1.31   "SNP" shall mean a single nucleotide polymorphism.

     1.32   "STATIN" shall mean a therapeutic compound that inhibits the
activity of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

     1.33   "STATIN RESPONSE GENE" shall mean a Candidate Gene that is part of a
Genaissance SR Association.

     1.34   "STATIN THERANOSTIC PRODUCT" shall mean any product or service that
(a) is intended for use in the prognosis of an individual's response (efficacy
or adverse drug reaction) to a Statin and (b) detects directly or indirectly (i)
one (1) or more Genetic Markers correlated with response to one or more Statins
or (ii) one (1) or more Surrogate Markers of such Genetic Markers. Statin
Theranostic Products include Class-wide Statin Theranostic Products and Non-[**]
Statin-specific Theranostic Products.

     1.35   "STRENGTH DATABASE" shall mean a database that is installed on the
Computer and that contains: (a) descriptions of Genaissance SR Associations
formatted in Excel spreadsheets; (b) a DECOGEN-accessible file containing the
clinical data obtained from the STRENGTH cohort for the Clinical Phenotypes
evaluated in the STRENGTH Trial; (c) a Word file containing the Clinical Data
Dictionary; (d) annotated genetic data (including Genetic Markers and
frequencies thereof) from the STRENGTH cohort for all Statin Response Genes.

     1.36   "STRENGTH TRIAL" shall mean the study undertaken by Genaissance as
described in EXHIBIT E to this Agreement.

     1.37   "TERM" shall have the meaning set forth in Section 9.1 hereof.

     1.38   "THERANOSTIC PRODUCT" shall mean a diagnostic test that will
facilitate individualized diagnostic and therapeutic follow-up to patients.

     1.39   "THIRD PARTY" shall mean any entity other than Genaissance or
AstraZeneca and their respective Affiliates.

                                    ARTICLE 2
                  DELIVERY AND USE OF THE STRENGTH DATABASE AND
                         DECOGEN(R) INFORMATICS PLATFORM

     2.1 DELIVERY OF THE COMPUTER AND TRAINING ON USE OF THE STRENGTH DATABASE
AND DECOGEN INFORMATICS PLATFORM. Within [**] business days after the Effective
Date, or thereafter at a date to be mutually agreed upon, Genaissance will
provide [**] days of training at Genaissance's facility in New Haven, CT on use
of the DECOGEN Informatics Platform, on the interpretation of the clinical data
and genetic data contained in the STRENGTH Database, and on the statistical
analyses performed in identifying the SR Associations. AstraZeneca shall bear
the costs of its employees who attend the training session. During that training
session,

<Page>

Genaissance shall also deliver to AstraZeneca the Computer that will contain the
STRENGTH Database and DECOGEN Informatics Platform.

     2.2 UPDATES TO THE STRENGTH DATABASE. Should Genaissance discover that any
of the data in the STRENGTH Database provided to AstraZeneca is inaccurate or
that the statistical analysis determined for any Genaissance SR Association
should be changed, Genaissance shall provide to AstraZeneca an update to the
STRENGTH Database within [**] days of such discovery at no cost to AstraZeneca.

     2.3 BUILDING OF HAP MARKERS FROM THE RESEARCH STUDY. At AstraZeneca's
request, Genaissance will build HAP Markers from the genotyping data from the
Research Study and deliver the data to AstraZeneca, within [**] of receiving
such data, along with protocols to upload the data into the DECOGEN Informatics
Platform for a fee stipulated in Section 4.3.

     2.4 TECHNICAL SUPPORT. Genaissance shall provide technical support through
a primary contact person who shall be accessible by telephone and e-mail between
the hours of 8:30 a.m. and 5:30 p.m. U.S. Eastern Time, Monday through Friday or
through additional on-site assistance. Genaissance's actual and reasonable
travel costs incurred in providing such additional on-site assistance shall be
reimbursed by AstraZeneca.

                                    ARTICLE 3
                                GRANTS OF RIGHTS

     3.1 Rights granted to AstraZeneca by Genaissance.

         3.1.1   NON-EXCLUSIVE RESEARCH LICENSE TO THE COMPUTER AND THE
GENAISSANCE BACKGROUND IP. Subject to the terms of this Agreement and for so
long as AstraZeneca is not in breach of any of such terms, Genaissance hereby
grants to AstraZeneca (and its Affiliates) during the Initial Term, and the
Extended Term, if any, a non-exclusive, fee-bearing license, without the right
to grant sublicenses, under Genaissance Patent Rights and Genaissance Know-How
to access and use the Genaissance Background IP on the Computer solely for
performing the Research Study and for publishing the results obtained therefrom.

         3.1.2   OPTION FOR EXTENDING RESEARCH LICENSE. Subject to the terms of
this Agreement and for so long as AstraZeneca is not in breach of any of such
terms, Genaissance hereby grants to AstraZeneca an option to extend the term of
the research license granted pursuant to Section 3.1.1 for one additional year
to allow AstraZeneca to complete the Research Study. AstraZeneca may exercise
this option by providing Genaissance written notice of such intent [**] days
prior to the end of the Initial Term and paying the Term Extension Fee set forth
in Section 4.2.

         3.1.3   RESTRICTIONS ON LICENSE TO THE STRENGTH DATABASE.

         (a) If AstraZeneca decides to perform the Research Study, AstraZeneca
shall prepare the Research Study plan and provide Genaissance a copy of the plan
prior to beginning the study. The Research Study plan shall be appended hereto
as Exhibit D. Within [**] days of completing

<Page>

the analysis of the Research Study, AstraZeneca shall provide Genaissance a
written report that describes in reasonable detail the results of the Research
Study with respect to any correlation, or lack of correlation, between Candidate
Genes and response to any of the Statins, EXCEPT [**] Specific Correlations, in
the Research Study. Both the Research Study Plan and subsequent report shall be
treated as the confidential information of AstraZeneca, provided, that, any
Genaissance SR Associations for non-[**] Statins shall not constitute
AstraZeneca information and PROVIDED FURTHER, THAT, Genaissance shall have the
right to disclose only such confidential information of AstraZeneca to the
extent reasonably necessary to exploit the non-exclusive license granted by
AstraZeneca pursuant to Section 3.2.1.

         (b) FOR THE AVOIDANCE OF DOUBT, the research license granted to
AstraZeneca in Section 3.1.1 does not include a license to use any data in the
STRENGTH Database, specifically including the Genaissance SR Associations and
the Genetic Markers contained therein, to conduct research for any purpose other
than as described in Section 3.1.1, or to develop or commercialize any Statin
Theranostic Products or therapeutic products.

         3.1.4   RESTRICTIONS ON USE OF THE COMPUTER AND THE GENAISSANCE
BACKGROUND IP. AstraZeneca's use of the Computer and the Genaissance Background
IP shall be subject to the following conditions:

         (a) The Computer may not be moved from the AstraZeneca installation
location specified in EXHIBIT B without the prior written authorization of
Genaissance;

         (b) To the extent that the DECOGEN Informatics Platform incorporates or
requires the use of any commercially available operating system software that is
licensed by Genaissance from a Third Party as described in EXHIBIT C, as may be
supplemented from time to time, AstraZeneca shall be responsible for obtaining
any necessary license and paying all fees and charges associated with
AstraZeneca's use of any such software;

         (c) AstraZeneca shall not use the Computer or Genaissance Background IP
to provide services for, or to process information for, any Third Party;

         (d) AstraZeneca agrees to make copies of the STRENGTH Database, or any
of the contents therein, only to the extent reasonably necessary to perform the
Research Study, and further agrees that all such copies will be treated as
Confidential Information of Genaissance;

         (e) AstraZeneca shall not delete or permit to be deleted any
identifying marks, copyright or proprietary right notices of Genaissance from
the Genaissance Background IP;

         (f) AstraZeneca shall not translate, decompile, nor create nor attempt
to create, by reverse engineering or otherwise, the source code from the object
code of the DECOGEN Informatics Platform, or adapt the DECOGEN Informatics
Platform in any way;

         (g) Except as specifically authorized hereunder, AstraZeneca shall not
sell, transfer, publish, disclose, display or otherwise make available any
portion of the DECOGEN Informatics Platform or STRENGTH Database, specifically
including the data contained therein, to Third Parties or permit Third Parties
to access the Computer; and

<Page>

         (h) AstraZeneca agrees to secure and protect the DECOGEN Informatics
Platform and STRENGTH Database in a manner reasonably consistent with the
maintenance of rights therein, and in accordance with the terms of this
Agreement, and to take appropriate action by instruction or agreement with its
employees who are permitted access to the Computer, DECOGEN Informatics Platform
or STRENGTH Database to satisfy its obligations hereunder. AstraZeneca shall
cooperate with and reasonably assist Genaissance in identifying and preventing
any unauthorized use, copying or disclosure of the DECOGEN Informatics Platform
or STRENGTH Database. AstraZeneca shall maintain records identifying the
specific individuals who have accessed the Computer, DECOGEN Informatics
Platform or Databases and shall make copies of same available to Genaissance
upon Genaissance's reasonable request.

     3.2 RIGHTS GRANTED TO GENAISSANCE BY ASTRAZENECA.

         3.2.1   NON-EXCLUSIVE LICENSE TO FOREGROUND IP. Subject to the terms of
this Agreement and subject to any pre-existing rights of AstraZeneca or Third
Parties, AstraZeneca hereby grants to Genaissance a fully-paid, perpetual
world-wide non-exclusive license, with the right to sublicense, to use
Foreground IP (excluding any data and intellectual property in respect of [**]
Specific Correlations) solely to research, develop, make, have made, use,
import, offer to sell and sell Class-wide Statin Theranostic Products and
Non-[**] Statin-specific Theranostic Products.

         3.2.2   RIGHT OF FIRST NEGOTIATION FOR ASTRAZENECA GENOTYPING SERVICES.
For a period of three (3) years from the Effective Date, if the Enabling Science
& Technology Research & Development Genetics Department of AstraZeneca decides
to outsource any new genotyping or haplotyping work to a Third Party, then
AstraZeneca shall provide Genaissance with written notice of such decision. If
Genaissance notifies AstraZeneca in writing within [**] days of notice of
AstraZeneca's decision ("Notice Period") that it wishes to exercise its right of
first negotiation, then Genaissance and AstraZeneca shall negotiate in good
faith for a period of up to [**] days commencing with the date of Genaissance's
notice (the "Negotiation Period"), a commercially reasonable term sheet for the
performance by Genaissance or its Affiliates of the genotyping or haplotyping
services. If Genaissance fails to exercise its right of first negotiation within
the Notice Period, or Genaissance informs AstraZeneca that it is not interested
in exercising its right of first negotiation under this Section 3.2.2 or the
Parties do not agree on commercially reasonable terms within the Negotiation
Period, then AstraZeneca shall be free to negotiate with Third Parties for such
genotyping or haplotyping services without any further obligation to
Genaissance.

For the purposes of clarity, the term "right of first negotiation" as used in
this Agreement means that the Parties shall negotiate in good faith the
commercially reasonable terms for a term sheet within the applicable Negotiation
Period, but does not mean that AstraZeneca is required to enter into a
definitive agreement. It is agreed that prior to or during any applicable
Negotiation Period, AstraZeneca may not, directly or indirectly, obtain or
solicit bids or clarifying information in connection therewith from Third
Parties.

         3.2.3   RIGHT OF FIRST NEGOTIATION TO COMMERCIALIZE [**]-SPECIFIC OR
CLASS-WIDE STATIN THERANOSTIC PRODUCT. For a period of three (3) years from the
Effective Date, if AstraZeneca decides to commercialize in partnership with a
third party: (a) [**]-specific

<Page>

diagnostic product or (b) Class-wide Statin diagnostic products then AstraZeneca
shall provide Genaissance with written notice of such decision. If Genaissance
notifies AstraZeneca in writing within [**] days of notice of AstraZeneca's
decision ("NOTICE PERIOD") that it wishes to exercise its right of first
negotiation, then Genaissance and AstraZeneca shall negotiate in good faith for
a period of up to [**] days commencing with the date of Genaissance's notice
(the "NEGOTIATION PERIOD"), a commercially reasonable term sheet for development
and commercialization of such diagnostic products. If Genaissance fails to
exercise its right of first negotiation within the Notice Period, or Genaissance
informs AstraZeneca that it is not interested in exercising its right of first
negotiation under this Section 3.2.3 or the Parties do not agree on commercially
reasonable terms within the Negotiation Period, then AstraZeneca shall be free
to negotiate with Third Parties for the development and commercialization of
such diagnostic products without any further obligation to Genaissance.

                 For the purposes of clarity, the term "right of first
negotiation" as used in this Agreement means that the Parties shall negotiate in
good faith the commercially reasonable terms for a term sheet within the
applicable Negotiation Period, but does not mean that AstraZeneca is required to
enter into a definitive agreement. It is agreed that prior to or during any
applicable Negotiation Period, AstraZeneca may not, directly or indirectly,
obtain or solicit bids or clarifying information in connection therewith from
Third Parties.

     3.3 NO GRANT OF OTHER TECHNOLOGY OR PATENT RIGHTS. Except as otherwise
expressly provided in this Agreement, under no circumstances shall a Party
hereto, as a result of this Agreement, obtain any ownership interest in or other
right to any technology, know-how, patents, patent applications, data, products,
or biological materials of the other Party, including items owned, controlled or
developed by the other Party, or transferred by the other Party to said Party,
at any time pursuant to this Agreement. Any compounds, technology or know-how
derived, developed or acquired by a Party independent of use of or access to the
other Party's intellectual property shall be the property of such Party.

                                    ARTICLE 4
                                    PAYMENTS

     4.1    INITIAL TERM LICENSE FEE. In consideration of the rights granted to
AstraZeneca under Article 3.1.1, AstraZeneca agrees to pay Genaissance a fee of
[**] U.S. dollars ($[**]) to be paid within thirty (30) days of the Effective
Date.

     4.2    TERM EXTENSION FEE. If AstraZeneca chooses to exercise the option
set forth in Section 3.1.2, AstraZeneca shall pay Genaissance a fee of [**] U.S.
dollars ($[**]) to be paid no later than the anniversary of the Effective Date.

     4.3    DATA INSTALLATION AND HAPLOTYPE BUILDING FEE. AstraZeneca shall pay
Genaissance for installing clinical data and genetic data from the AstraZeneca
clinical trials into the AstraZeneca Proprietary Database, and for building
Haplotypes from such genetic data, for a fee of [**] dollars ($[**]) for the
entire Research Study.

<Page>

     4.4    CONSULTATION FEE. If AstraZeneca requests that Genaissance provide
consulting services with respect to design of the Research Study Plan,
AstraZeneca shall pay a fee of [**] dollars ($[**]) for such consulting
services.

     4.5    MANNER OF PAYMENT. Payments to be made by AstraZeneca to Genaissance
under this Agreement shall be payable in United States dollars and shall be paid
by bank wire transfer in immediately available funds to such bank account in the
State of Connecticut as is designated in writing by Genaissance from time to
time.

                                    ARTICLE 5
                              INTELLECTUAL PROPERTY

     5.1    OWNERSHIP OF INTELLECTUAL PROPERTY

            5.1.1 OWNERSHIP OF THE STRENGTH DATABASE AND DECOGEN INFORMATICS
PLATFORM. Subject to the rights and licenses granted under this Agreement, and
subject to any pre-existing rights of AstraZeneca or Third Parties, Genaissance
shall have sole ownership of (i) the STRENGTH Database and (ii) the DECOGEN
Informatics Platform.

            5.1.2 OWNERSHIP OF GENAISSANCE SR ASSOCIATIONS. Subject to the
rights and licenses granted under this Agreement, and subject to any
pre-existing rights of AstraZeneca or Third Parties, Genaissance shall have sole
ownership of all right, title and interest in all Genaissance SR Associations
and all Patent Rights for such Associations.

            5.1.3 OWNERSHIP OF FOREGROUND IP. AstraZeneca shall have sole
ownership of all right, title and interest in all Foreground IP.

     5.2    COOPERATION OF EMPLOYEES. Each Party represents and agrees that all
employees or others acting on its behalf pursuant to this Agreement shall be
obligated under a binding written agreement to assign to such Party all
inventions made or conceived by such employee or other person.

                                    ARTICLE 6
                                 CONFIDENTIALITY

     6.1 CONFIDENTIAL INFORMATION. Confidential Information shall mean, subject
to the limitations and exceptions described in Section 6.2.2, (i) any
information and data received by a Party from the other Party in connection with
the performance of this Agreement (and which, in the case of AstraZeneca as
recipient, shall include without limitation the STRENGTH Database and all
information contained therein and the DECOGEN Informatics Platform, and which,
in the case of Genaissance as recipient, shall include without limitation any
information and data relating to AstraZeneca's research and development efforts
using the STRENGTH Database and the DECOGEN Informatics Platform, except as
provided in Section 3.1.3, as well as any research, testing, clinical,
regulatory, marketing or other scientific or business information, plans or data
pertaining to any product of AstraZeneca) and (ii) all information and data not
described in clause (i) but supplied by either Party in connection with this
Agreement and marked "Confidential."

<Page>

     6.2 NONDISCLOSURE OBLIGATIONS.

         6.2.1   GENERAL. Except as otherwise provided in this Article 6, during
the term of this Agreement and for a period of ten (10) years thereafter, the
parties shall maintain the Confidential Information in confidence and use it
only for purposes specifically authorized under this Agreement.

         6.2.2   LIMITATIONS. The Parties agree that the receiving Party shall
not have any obligation of confidentiality with respect to such Confidential
Information that: (a) is or becomes part of the public domain other than by
unauthorized acts of the Party obligated not to disclose such Confidential
Information; (b) can be shown by written documents to have been disclosed to the
receiving Party by a Third Party, provided such Confidential Information was not
obtained by such Third Party directly or indirectly from the other Party to this
Agreement pursuant to a confidentiality agreement; (c) prior to disclosure under
this Agreement, was already in the possession of the receiving Party, provided
such Confidential Information was not obtained directly or indirectly from the
other Party to this Agreement pursuant to a confidentiality agreement; (d) can
be shown by written documents to have been independently developed by the
receiving Party without breach of any of the provisions of this Agreement; (e)
is disclosed by the receiving Party pursuant to an order or demand issued by a
court or governmental agency or as otherwise required by law; PROVIDED, HOWEVER,
that the receiving Party notifies the other Party prior to disclosure, giving
such other Party sufficient advance notice to permit it to seek a protective
order or other similar order with respect to such Confidential Information AND
PROVIDED, FURTHER, that the receiving Party furnishes only that portion of the
Confidential Information which it is advised by counsel is legally required
whether or not a protective order or other similar order is obtained by the
other Party; or (f) where the receiving Party reasonably believes such
disclosure is reasonably necessary or appropriate to fulfill its obligations or
exercise its rights under this Agreement, with such disclosure being limited to:
(i), consultants, outside contractors and clinical investigators, on a
need-to-know basis and on condition that such entities or persons agree to keep
the Confidential Information confidential for the same time periods and to the
same extent as such Party is required to keep the Confidential Information
confidential; and (ii) government or other regulatory authorities to the extent
that such disclosure is reasonably necessary to obtain patents or authorizations
to conduct clinical trials of, and to commercially market, products pursuant to
this Agreement.

     6.3 INJUNCTIVE RELIEF. The parties hereto understand and agree that
remedies at law may be inadequate to protect against any breach of any of the
provisions of this Article 6 by either Party or their employees, agents,
officers or directors or any other person acting in concert with it or on its
behalf. Accordingly, each Party may be entitled to the granting of injunctive
relief by a court of competent jurisdiction against any action that constitutes
any such breach of this Article 6.

     6.4    PUBLICATION. The decision to publish any results of the Research
Study will be made at the sole discretion of AstraZeneca. Where appropriate,
AstraZeneca will invite Genaissance to co-author scientific papers, but all
final decisions on the content of publications will be made at the sole
discretion of AstraZeneca. Notwithstanding the foregoing, in the event a
proposed publication or presentation contains confidential information of
Genaissance, AstraZeneca shall furnish Genaissance a copy of any such proposed
publication or presentation

<Page>

at least thirty (30) days prior to submission for publication or presentation,
and upon Genaissance's request during this thirty day period, AstraZeneca shall
delete any information that constitutes confidential information of Genaissance.

                                    ARTICLE 7
                         REPRESENTATIONS AND WARRANTIES

     7.1    REPRESENTATIONS, WARRANTIES AND COVENANTS OF GENAISSANCE.
Genaissance represents and warrants to and covenants with AstraZeneca that:

            (a)  Genaissance is a corporation duly organized, validly existing
and in corporate good standing under the laws of Delaware;

            (b)  Genaissance has the legal right, authority and power to enter
into this Agreement, and to extend the rights and licenses granted to
AstraZeneca in this Agreement;

            (c)  Genaissance has taken all necessary action to authorize the
execution, delivery and performance of this Agreement;

            (d)  upon the execution and delivery of this Agreement, this
Agreement shall constitute a valid and binding obligation of Genaissance
enforceable in accordance with its terms, except as enforceability may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting creditors' and contracting parties' rights generally and
except as enforceability may be subject to general principles of equity
(regardless of whether such enforceability is considered in a proceeding in
equity or at law);

            (e)  the performance of its obligations under this Agreement will
not conflict with its charter documents or result in a breach of any agreements,
contracts or other arrangements to which it is a party;

            (f)  to the best of Genaissance's knowledge but without independent
investigation, the performance of Genaissance's obligations under this Agreement
will not infringe, or shall be exempt from infringement of, any issued patent or
valid copyright of any Third Party; and

            (g)  Genaissance will not during the term of this Agreement enter
into any agreements, contracts or other arrangements that would be inconsistent
with its obligations under this Agreement.

     7.2    REPRESENTATIONS, WARRANTIES AND COVENANTS OF ASTRAZENECA.
AstraZeneca represents and warrants to and covenants with Genaissance that:

            (a)  AstraZeneca is a corporation duly organized, validly existing
and in corporate good standing under the laws of the England and Wales;

            (b)  AstraZeneca has the legal right, authority and power to enter
into this Agreement, and to extend the rights and licenses granted to
Genaissance in this Agreement;

            (c)  AstraZeneca has taken all necessary action to authorize the
execution, delivery and performance of this Agreement;

<Page>

            (d)  upon the execution and delivery of this Agreement, this
Agreement shall constitute a valid and binding obligation of AstraZeneca
enforceable in accordance with its terms, except as enforceability may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting creditors' and contracting parties' rights generally and
except as enforceability may be subject to general principles of equity
(regardless of whether such enforceability is considered in a proceeding in
equity or at law);

            (e)  the performance of its obligations under this Agreement will
not conflict with AstraZeneca's charter documents or result in a breach of any
agreements, contracts or other arrangements to which it is a party; and

            (f)  AstraZeneca will not after the Effective Date enter into any
agreements, contracts or other arrangements that would be inconsistent with its
obligations under this Agreement.

     7.3 WARRANTY DISCLAIMER. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS
AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO THE STRENGTH
DATABASE, DECOGEN INFORMATICS PLATFORM, PATENT RIGHTS, GOODS, SERVICES OR OTHER
SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT WITH
RESPECT TO ANY AND ALL OF THE FOREGOING. GENAISSANCE MAKES NO REPRESENTATION OR
WARRANTIES WITH RESPECT TO ASTRAZENECA'S USE OF THE INFORMATION TO BE PROVIDED
TO IT HEREUNDER. GENAISSANCE MAKES NO WARRANTY THAT THE STRENGTH DATABASE DOES
NOT CONTAIN ERRORS.

     7.4 LIMITED LIABILITY. NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT OR
OTHERWISE TO THE CONTRARY, NEITHER GENAISSANCE NOR ASTRAZENECA WILL BE LIABLE
WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT UNDER ANY CONTRACT,
NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR (I) ANY
PUNITIVE, EXEMPLARY, INCIDENTAL OR CONSEQUENTIAL DAMAGES OR LOST PROFITS OR (II)
COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES.

                                    ARTICLE 8
                                    INDEMNITY

     8.1    ASTRAZENECA INDEMNITY OBLIGATIONS. AstraZeneca will, at its own
expense, indemnify and promptly reimburse Genaissance for the defense of, and
hold harmless Genaissance and its officers and employees, from and against any
and all claims, actions, liabilities, losses, damages, judgments, grants, costs
and expenses (including attorneys' fees) to the extent resulting from (a)
AstraZeneca's gross negligence or intentional misconduct in its use or operation
of the Genaissance SR Associations, DECOGEN Informatics Platform, STRENGTH
Database or Computer or (b) a material breach of any of the warranties made
hereunder by AstraZeneca except and to the extent that Genaissance has an
obligation to indemnify AstraZeneca pursuant to section 8.2.

<Page>

     8.2    GENAISSANCE INDEMNITY OBLIGATIONS. Genaissance agrees to defend,
indemnify and hold AstraZeneca, its officers and its employees and agents
harmless from and against any and all claims, actions, losses, damages,
judgments, grants or expenses (including attorneys' fees) to the extent
resulting from : (a) Genaissance's use of the licensed Foreground IP, (b) claims
by employees or contractors of Genaissance for bodily injury, death or property
damage arising out of the performance by Genaissance of any activities under
this Agreement; (c) the negligence, recklessness or intentional misconduct of
Genaissance in connection with its activities under this Agreement or (d) a
material breach of any of the warranties made hereunder by Genaissance except
and to the extent that AstraZeneca has an obligation to indemnify Genaissnace
pursuant to Section 8.1..

     8.3    LIMITATION ON INDEMNITY OBLIGATIONS. Neither Party and its
respective employees and agents shall be entitled to the indemnities set forth
in Section 8.1 and Section 8.2 where the claim, loss, damage or expense for
which indemnification is sought was caused by a grossly negligent or intentional
act or omission by the other Party, its directors, officers, employees or
authorized agents.

     8.4    PROCEDURE. If the Party being indemnified hereunder or its
respective employees or agents (the "Indemnitee") intends to claim
indemnification under this Article 8, the Indemnitee shall promptly notify the
other Party (the "Indemnitor") of any loss, claim, damage, liability or action
in respect of which the Indemnitee intends to claim such indemnification, and
the Indemnitor shall assume the defense thereof with counsel mutually
satisfactory to the parties; PROVIDED, HOWEVER, that an Indemnitee shall have
the right to retain its own counsel, with the fees and expenses to be paid by
the Indemnitor, if representation of such Indemnitee by the counsel retained by
the Indemnitor would be inappropriate due to actual or potential differing
interests between such Indemnitee and any other party represented by such
counsel in such proceedings. The indemnity agreement in this Article 8 shall not
apply to amounts paid in settlement of any loss, claim, damage, liability or
action if such settlement is effected without the consent of the Indemnitor,
which consent shall not be withheld unreasonably. The failure to deliver notice
to the Indemnitor within a reasonable time after the commencement of any such
action, if prejudicial to its ability to defend such action, shall relieve such
Indemnitor of any liability to the Indemnitee under this Article 8, but the
omission so to deliver notice to the Indemnitor will not relieve it of any
liability that it may have to any Indemnitee otherwise than under this Article
8. The Indemnitee under this Article 8, its employees and agents, shall
cooperate fully with the Indemnitor and its legal representatives in the
investigation of any action, claim or liability covered by this indemnification.
The Indemnitor shall additionally be liable to pay the reasonable legal costs
and attorneys' fees incurred by the Indemnitee in establishing its claim for
indemnity.

                                    ARTICLE 9
                           EXPIRATION AND TERMINATION

     9.1    TERM OF AGREEMENT. Unless this Agreement is sooner terminated in
accordance with the provisions of this Article 9, the "Term" of this Agreement
shall commence on the Effective Date and expire one (1) year from the Effective
Date or, if extended pursuant to Section 3.1.2, shall expire two (2) years from
the Effective Date.

<Page>

     9.2    EVENTS OF DEFAULT.

            9.2.1 DEFAULT BY EITHER PARTY. An Event of Default shall have
occurred upon (i) the occurrence of a material breach of this Agreement (other
than an Event of Default described in Section 9.3.2) if the breaching Party
fails to remedy such breach within thirty (30) days after written notice thereof
by the non-breaching Party (or if such breach cannot be cured within such thirty
(30) day period the breaching party does not commence action to cure such breach
and continue thereafter to diligently continue such actions) or (ii) the
bankruptcy, insolvency, dissolution or winding up of a Party.

            9.2.2 DEFAULT BY ASTRAZENECA. An Event of Default shall have
occurred if AstraZeneca fails to make any payments due hereunder, thirty (30)
business days after Genaissance delivers written notice thereof to AstraZeneca
specifying such failure and its claim of right to terminate, unless AstraZeneca
makes such payments plus interest within such thirty (30) day period.

     9.3    EFFECT OF AN EVENT OF DEFAULT.

            9.3.1 REMEDIES AVAILABLE TO GENAISSANCE. In the event that an Event
of Default occurs relating to AstraZeneca and AstraZeneca fails to cure such
default during any applicable cure period, Genaissance shall have the right, at
its option exercisable in its sole discretion, in addition to any other rights
or remedies available to it at law or in equity, to terminate this Agreement
upon notice thereof to AstraZeneca, in which case (i) the options and licenses
granted to AstraZeneca pursuant to Section 3.1 shall terminate and (ii) any and
all information and materials provided by Genaissance pursuant to this Agreement
(including, without limitation, all copies of the STRENGTH Database and DECOGEN
Informatics Platform), and any copies thereof (including electronic copies)
shall be promptly returned by AstraZeneca to Genaissance, and AstraZeneca shall
delete all copies of the STRENGTH Database and DECOGEN Informatics Platform from
all computers at its site on which such information has been installed or
transmitted.

            9.3.2 REMEDIES AVAILABLE TO ASTRAZENECA. In the event that an Event
of Default occurs relating to Genaissance and Genaissance fails to cure such
default within the applicable cure period, then AstraZeneca shall have the
right, at its option exercisable in its sole discretion, (i) to terminate this
Agreement upon notice thereof to Genaissance in which case (ii) the license and
rights granted to Genaissance pursuant to Section 3.2 shall terminate and (iii)
any and all information and materials provided by AstraZeneca shall be promptly
returned to AstraZeneca.

     9.4    EFFECT OF TERMINATION. Upon termination of this Agreement,
            AstraZeneca shall destroy all copies of the STRENGTH Database and
            the DECOGEN Informatics Platform, return the Computer to
            Genaissance, and certify the completion of such steps in writing to
            Genaissance. The termination of the Agreement shall automatically,
            and without further action by Genaissance, terminate and extinguish
            the license rights granted pursuant to Section 3.1. The expiration
            or termination of this Agreement shall not relieve the Parties of
            any obligation accruing prior to such expiration or termination. The
            provisions of Articles 5, 6, 8, 9 and 10, Sections 7.3 and 7.4
            hereof, and the licenses and rights granted to

<Page>

            either Party pursuant to Article 3 hereof shall survive the
            expiration or termination of this Agreement.

                                   ARTICLE 10
                                  MISCELLANEOUS

     10.1   FORCE MAJEURE. Neither Party shall be held liable or responsible to
the other Party nor be deemed to have defaulted under or breached this Agreement
for failure or delay in fulfilling or performing any term of this Agreement when
such failure or delay is caused by or results from causes beyond the reasonable
control of the affected Party, including but not limited to fire, floods,
embargoes, war, acts of war (whether war is declared or not), insurrections,
riots, civil commotions, strikes, lockouts or other labor disturbances, acts of
God or acts, omissions or delays in acting by any governmental authority or the
other Party; PROVIDED, HOWEVER, that the Party so affected shall use reasonable
commercial efforts to avoid or remove such causes of nonperformance, and shall
continue performance hereunder with reasonable dispatch whenever such causes are
removed. Either Party shall provide the other Party with prompt written notice
of any delay or failure to perform that occurs by reason of FORCE MAJEURE. The
Parties shall mutually seek a resolution of the delay or the failure to perform
as noted above.

     10.2   ASSIGNMENT. This Agreement may not be assigned or otherwise
transferred by either Party without the consent of the other Party, such consent
not to be unreasonably withheld or delayed; PROVIDED, HOWEVER, that either
Genaissance or AstraZeneca may, without such consent, assign its rights and
obligations under this Agreement (i) to any Affiliate, or (ii) in connection
with a merger, consolidation or sale of substantially all of such Party's assets
to an unrelated Third Party; PROVIDED, HOWEVER, that such Party's rights and
obligations under this Agreement shall be assumed by its successor in interest
in any such transaction and shall not be transferred separate from all or
substantially all of its other business assets, including those business assets
that are the subject of this Agreement. Any purported assignment in violation of
the preceding sentence shall be void. Any permitted assignee shall assume all
obligations of its assignor under this Agreement.

     10.3   SEVERABILITY. Each Party hereby agrees that it does not intend to
violate any public policy, statutory or common laws, rules, regulations, treaty
or decision of any government agency or executive body thereof of any country or
community or association of countries. Should one or more provisions of this
Agreement be or become invalid, the Parties hereto shall substitute, by mutual
consent, valid provisions for such invalid provisions which valid provisions in
their economic effect are sufficiently similar to the invalid provisions that it
can be reasonably assumed that the Parties would have entered into this
Agreement with such valid provisions. In case such valid provisions cannot be
agreed upon, the invalidity of one or several provisions of this Agreement shall
not affect the validity of this Agreement as a whole, unless the invalid
provisions are of such essential importance to this Agreement that it is to be
reasonably assumed that the parties would not have entered into this Agreement
without the invalid provisions.

     10.4   NOTICES. Any consent, notice or report required or permitted to be
given or made under this Agreement by one of the Parties hereto to the other
shall be in writing, delivered personally or by facsimile (and promptly
confirmed by telephone, personal delivery or courier) or courier, postage
prepaid (where applicable), addressed to such other Party at its address

<Page>

indicated below, or to such other address as the addressee shall have last
furnished in writing to the addressor and shall be effective upon receipt by the
addressee.

     If to Genaissance:       Genaissance Pharmaceuticals, Inc.
                              Five Science Park
                              New Haven, CT  06511
                              Attention: Chief Executive Officer
                              Telephone: (203) 773-1450
                              Facsimile: (203) 562-9377

     With a copy to:          Melodie Henderson
                              Five Science Park
                              New Haven, CT  06511

     If to AstraZeneca:       AstraZeneca UK Limited.
                              Enabling Sciences and Technology
                              Mereside Alderley Park
                              Macclesfield Cheshire SK10 4TG
                              United Kingdom
                              Attention: Assistant General Counsel
                              Facsimile: +44 (1625) 585618

     10.5   APPLICABLE LAW. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware, without giving effect to the
choice of laws provisions thereof.

     10.6   DISPUTE RESOLUTION.

            10.6.1 The Parties hereby agree that they will attempt in good faith
to resolve any controversy or claim arising out of or relating to this Agreement
promptly by negotiations. If a controversy or claim should arise hereunder, the
matter shall be referred to an individual designated by the Chief Executive
Officer (or the equivalent position) of Genaissance and an individual designated
by the Enabling Science & Technology (or the equivalent position) of AstraZeneca
(the "Representatives"). If the matter has not been resolved within [**] days of
the first meeting of the Representatives of the Parties (which period may be
extended by mutual agreement) concerning such matter, subject to rights to
injunctive relief and specific performance, and unless otherwise specifically
provided for herein, any controversy or claim arising out of or relating to this
Agreement, or the breach thereof, will be settled as set forth in Section
10.6.2.

            10.6.2 All disputes arising in connection with this Agreement shall
be finally settled by binding arbitration conducted in New York, New York under
the Commercial Arbitration Rules of the American Arbitration Association by a
single arbitrator appointed in accordance with said Rules. Notwithstanding the
above, either Party has the right to bring suit in a court of competent
jurisdiction against the other Party for (i) any breach of such other Party's
duties of confidentiality pursuant to Article 6 of this Agreement and (ii) any
infringement of its own proprietary rights by the other Party. Judgment upon the
arbitrator's award may be entered

<Page>

in any court of competent jurisdiction. The award of the arbitrator may include
compensatory damages against either Party, but under no circumstances will the
arbitrator be authorized to, nor shall he, award punitive damages or multiple
damages against either Party. The parties agree not to institute any litigation
or proceedings against each other in connection with this Agreement except as
provided in this Section 10.6.

     10.7   ENTIRE AGREEMENT. This Agreement, together with the exhibits hereto,
contains the entire understanding of the Parties with respect to the subject
matter hereof. All express or implied agreements and understandings, either oral
or written, heretofore made are expressly merged in and made a part of this
Agreement. This Agreement may be amended, or any term hereof modified, only by a
written instrument duly executed by both Parties hereto.

     10.8   Publicity.

            10.8.1 AGREEMENT. Except as required by law, and subject to Section
10.8.2, Genaissance and AstraZeneca each agree not to disclose the existence or
any terms or conditions of this Agreement to any Third Party without the prior
written permission of the other Party; PROVIDED, THAT either Party may make such
disclosures to its financial and legal advisers or actual or potential
investors, acquirors, licensees or sublicensees on a need to know basis and
subject to a confidentiality agreement. In the event that this Agreement shall
be included in any report, statement or other document filed by either Party or
an Affiliate of either Party with the United States Securities and Exchange
Commission (the "SEC"), such Party shall provide the other Party with reasonable
notice and shall use, or shall cause its Affiliate, as the case may be, to use,
reasonable efforts to obtain confidential treatment from the SEC of any
financial information or other information of a competitive or confidential
nature, and shall include in such confidentiality request such provisions of
this Agreement as may be reasonably requested by the other Party.

            10.8.2 PRESS RELEASE. Notwithstanding the foregoing, Genaissance and
AstraZeneca agree that a press release may be issued promptly after execution of
this Agreement by either Party in the form(s) agreed by the Parties and as set
forth in EXHIBIT F attached hereto. The Parties agree that any announcement by
either Party will not contain confidential business or technical information
and, if disclosure of confidential business or technical information is required
by law or regulation, will make commercially reasonable efforts to minimize such
disclosure and obtain confidential treatment for any such information which is
disclosed to a governmental agency or group. Each Party agrees to provide to the
other Party a copy of any public announcement with respect to this Agreement or
the subject matter of this Agreement as soon as reasonably practicable under the
circumstances prior to its scheduled release. Except under extraordinary
circumstances, each Party shall provide the other Party with an advance copy of
any such press release at least fourteen (14) days business days prior to the
scheduled disclosure. Each Party shall have the right to review and recommend
changes to any announcement regarding this Agreement or the subject matter of
this Agreement. Except as otherwise required by law, the Party whose press
release has been reviewed shall remove any information the reviewing Party
reasonably deems to be inappropriate for disclosure and shall use all reasonable
efforts to accommodate the reviewing Party's other comments. Neither Party shall
release any announcement with respect to this Agreement or the subject matter of
this Agreement with which the other Party has reasonable objection. The contents
of any such

<Page>

announcement or similar publicity which has been reviewed and approved by the
reviewing Party can be re-released by either Party without a requirement for
re-approval.

     10.9   HEADINGS. The captions to the several Articles and Sections hereof
are not a part of this Agreement, but are merely guides or labels to assist in
locating and reading the several Articles and Sections hereof.

     10.10  NO PARTNERSHIP. It is expressly agreed that the relationship between
Genaissance and AstraZeneca shall not constitute a partnership, joint venture or
agency. Neither Genaissance nor AstraZeneca shall have the authority to make any
statements, representations or commitments of any kind, or to take any action,
which shall be binding on the other, without the prior consent of the other
Party to do so.

     10.11  EXPORTS. The parties acknowledge that the export of technical data,
materials or products is subject to the exporting Party receiving any necessary
export licenses and that the parties cannot be responsible for any delays
attributable to export controls which are beyond the reasonable control of
either Party. Genaissance and AstraZeneca agree not to export or re-export,
directly or indirectly, any information, technical data, the direct product of
such data, samples or equipment received or generated under this Agreement in
violation of any applicable export control laws or governmental regulations.
Genaissance and AstraZeneca agree to obtain similar covenants from their
licensees, sublicensees and contractors with respect to the subject matter of
this Section.

     10.12  WAIVER. The waiver by either Party hereto of any right hereunder or
the failure to perform or of a breach by the other Party shall not be deemed a
waiver of any other right hereunder or of any other breach or failure by said
other Party whether of a similar nature or otherwise.

     10.13  COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

<Page>

     IN WITNESS WHEREOF, the parties have caused their duly authorized officer
to execute and deliver this Agreement as of the date first set forth above.

ASTRAZENECA UK LIMITED             GENAISSANCE PHARMACEUTICALS, INC.

By:  /s/ Dr. Rakesh Anand          By:  /s/ Krishnan Nandabalan, Ph.D.
   ---------------------------         ---------------------------------

Name: Dr Rakesh Anand              Name: Krishnan Nandabalan, Ph.D.

Title: Head of R&D Genetics        Title: Vice President, Business Development

Date: 9/5/03                       Date: 9/5/03
      ------------------------          --------------------------------

<Page>

                                    EXHIBIT A

                            ASSOCIATION SUMMARY TABLE

                         (To be Provided by Genaissance)

<Page>

                                    EXHIBIT B

                         Computer Installation Location
                         (To be supplied by AstraZeneca)

<Page>

                                    EXHIBIT C

                  Description of the DECOGEN Informatics System

DECOGEN Browser Software

     DESCRIPTION: The DECOGEN Browser software allows a user to browse genes,
     polymorphism data and clinical data; perform association analysis;
     calculate linkage disequilibrium; view Haplotype phylogenies; create and
     save projects based on clinical cohorts. Statistical analyses are run using
     SAS.

     ASTRAZENECA PROVIDES: Appropriate Oracle license, database administrator
     support for (DBA) for installation and data updates; a server and license
     for SAS.

DECOGEN DataManager Software

     DESCRIPTION: The DECOGEN DataManager software allows a user to browse genes
     and polymorphism data, in more detail than provided by the DECOGEN Browser
     software, but does not include any clinical analysis tools. DECOGEN
     DataManager software provides full access to the STRENGTH Database and has
     tools for importing a variety of data including SNPs, genotypes and
     Haplotypes for any gene whose structure is in the STRENGTH Database or the
     AstraZeneca Proprietary Database. Polymorphism and other types of data in
     the STRENGTH Database may also be exported using DECOGEN DataManager. This
     software does not include any clinical analysis tools.

     ASTRAZENECA PROVIDES: Appropriate Oracle license, database administrator
     support for (DBA) for installation and data updates.

<Page>

                                    EXHIBIT D

                               Research Study Plan

                         (To be provided by AstraZeneca)

<Page>

                                    EXHIBIT E

                                 STRENGTH TRIAL

     The STRENGTH Trial consists of the STRENGTH I trial, which was an
open-label examination of the relationship between treatment response and
Genetic Markers. Various efficacy and safety endpoints were measured before and
after treatment of seven hundred ninety-six (796) patients with one of three (3)
Statins: atorvastatin calcium (Lipitor), pravastatin sodium (Pravachol), and
simvastatin (Zocor). Subjects were administered the recommended starting dose of
one of these statins for eight (8) weeks and then administered the highest
allowed dose, according to the drug label, for an additional eight (8) weeks.

     All patients were sequenced for one hundred one (101) genes known or
believed to play a role in lipid metabolism, lipid trafficking, energy
metabolism, and inflammation. Additionally, all patients were genotyped for SNPs
from ADME Genes (some of which are also contained in the set of 101 sequenced
Genes). The genotyping and sequencing information derived is then used to assign
specific pairs of Haplotypes to each of the STRENGTH Trial patients for all of
the Genes.

<Page>

                                    EXHIBIT F

                                  PRESS RELEASE

Contact:

Kevin Rakin                                           Rhonda Chiger (investors)
President & Chief Executive Officer                   Rx Communications
Genaissance Pharmaceuticals, Inc.                     917.322.2569
203.786.3404                                          rchiger@RxIR.com
k.rakin@genaissance.com

NOT FOR IMMEDIATE RELEASE

    GENAISSANCE PHARMACEUTICALS AND ASTRAZENECA) SIGN PHARMACOGENOMICS BASED
                                    AGREEMENT

       - AGREEMENT CONTINUES THE COMMERCIALIZATION OF THE STRENGTH STUDY -

New Haven, CT, July XX, 2003 - Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC)
today announced that it has entered into a licensing agreement with AstraZeneca
PLC (NYSE: AZN) to utilize information generated from Genaissance's Statin
Response Examined by Genetic Haplotype Markers (STRENGTH) study. Under the terms
of the agreement, AstraZeneca will receive non-exclusive access to the STRENGTH
study database for research purposes for a limited period. This marks the second
commercialization agreement related to the proprietary data generated in
Genaissance's STRENGTH study.

"We are pleased to enter into this new agreement with AstraZeneca" said Kevin
Rakin, President and CEO of Genaissance. "Such agreements demonstrate our
continued effort to commercialize and build on our internal programs such as
STRENGTH".

The licensing arrangement is focused on proprietary data generated in the
STRENGTH study. This study of more than 400 patients demonstrated that gene
variations are associated with response to treatment with the Statin class of
drugs. Conducted over 16 weeks, the STRENGTH study prospectively analyzed for an
association between an individual's genetics and the clinical effectiveness of
three Statins (atorvastatin, pravastatin and simvastatin) in reducing
LDL-cholesterol. Initial results of this study were presented at the 52nd Annual
American College of Cardiology Scientific Session in March 2003.

<Page>

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of
human gene variation for the development of personalized medicines and DNA-based
diagnostics. Genaissance markets its technology, clinical development skills and
pharmacogenetic services to the pharmaceutical industry as a complete solution
for improving the development, marketing and prescribing of drugs. Genaissance
has agreements with major pharmaceutical, diagnostic and biotechnology
companies. Genaissance is headquartered in Science Park in New Haven,
Connecticut.

THIS PRESS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS, INCLUDING STATEMENTS
ABOUT THE EXPECTED GROWTH AND DEVELOPMENT OF GENAISSANCE'S BUSINESS, THE ABILITY
OF GENAISSANCE TO APPLY ITS TECHNOLOGIES TO THE DEVELOPMENT, MARKETING AND
PRESCRIBING OF DRUGS AND TO DETECT ASSOCIATIONS BETWEEN CLINICAL OUTCOMES AND
GENETIC VARIATION. SUCH STATEMENTS ARE SUBJECT TO CERTAIN FACTORS, RISKS AND
UNCERTAINTIES THAT MAY CAUSE ACTUAL RESULTS, EVENTS AND PERFORMANCE TO DIFFER
MATERIALLY FROM THOSE REFERRED TO IN SUCH STATEMENTS, INCLUDING, BUT NOT LIMITED
TO, THE EXTENT TO WHICH GENETIC MARKERS (HAPLOTYPES) ARE PREDICTIVE OF CLINICAL
OUTCOMES AND DRUG EFFICACY AND SAFETY, THE ATTRACTION OF NEW BUSINESS AND
STRATEGIC PARTNERS, THE ADOPTION OF OUR TECHNOLOGIES BY THE PHARMACEUTICAL
INDUSTRY, THE TIMING AND SUCCESS OF CLINICAL TRIALS, COMPETITION FROM
PHARMACEUTICAL, BIOTECHNOLOGY AND DIAGNOSTICS COMPANIES, THE STRENGTH OF OUR
INTELLECTUAL PROPERTY RIGHTS AND THOSE RISKS IDENTIFIED IN OUR ANNUAL REPORT ON
FORM 10-K FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 31, 2003
AND OUR QUARTERLY REPORTS ON FORM 10-Q AS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION FROM TIME TO TIME. THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN
REPRESENT THE JUDGMENT OF GENAISSANCE AS OF THE DATE OF THIS RELEASE.
GENAISSANCE DISCLAIMS ANY OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENT.

                                       ###QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.1    
    

 
 

Momenta Pharmaceuticals, Inc.
  
    Incentive Stock Option Agreement
  Granted Under 2004 Stock Incentive Plan    
    

1.     Grant of Option. 

        This
agreement evidences the grant by Momenta Pharmaceuticals, Inc., a Delaware corporation (the "Company"), on
[                        ],
200[    ] (the "Grant Date") to [                        ], an employee of the Company (the "Participant"), of
an option to purchase, in whole or in
part, on the terms provided herein and in the Company's 2004 Stock Incentive Plan (the "Plan"), a total of
[                        ] shares (the "Shares") of common stock, $0.0001 par
value per share, of the Company ("Common Stock") at $[            ] per Share. Unless earlier terminated, this option shall expire at 5:00 p.m., Eastern time, on
[                        ] (the "Final Exercise Date"). 

        It
is intended that the option evidenced by this agreement shall be an incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended, and any
regulations promulgated thereunder (the "Code"). Except as otherwise indicated by the context, the term "Participant", as used in this option, shall be deemed to include any person who acquires the
right to exercise this option validly under its terms. 

2.     Vesting Schedule. 

        This
option will become exercisable ("vest") as to [    ]% of the original number of Shares on the  [          ]
 anniversary of the Grant Date and as to an additional  [      ]% of the original number of Shares at the end of each successive  [            ] period following the first anniversary of the Grant Date until the  
[            ] anniversary of the Grant Date.
 

        The
right of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole
or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the termination of this option under Section 3 hereof or the Plan. 

3.     Exercise of Option. 

        (a)    Form of Exercise.    Each election to exercise this option shall be by written
notice in the form attached hereto as Exhibit A, in writing, signed by the Participant, and received by the Company at its principal office, accompanied by this
agreement, and payment in full in the manner provided in the Plan. The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be
for any fractional share. 

        (b)    Continuous Relationship with the Company Required.    Except as otherwise provided
in this Section 3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee or
officer of, or consultant or advisor to, the Company or any parent or subsidiary of the Company as defined in Section 424(e) or (f) of the Code (an "Eligible Participant"). 

        (c)    Termination of Relationship with the Company.    If the Participant ceases to be
an Eligible Participant for any reason, then, except as provided in paragraphs (d) and (e) below, the right to exercise this option shall terminate three months after such cessation (but
in no event after the Final Exercise Date), provided that this option shall be exercisable only to the extent that the Participant was entitled to
exercise this option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the non-competition or confidentiality
provisions 

of
any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon
written notice to the Participant from the Company describing such violation. 

        (d)    Exercise Period Upon Death or Disability.    If the Participant dies or becomes
disabled (within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship
for "cause" as specified in paragraph (e) below, this option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant
(or in the case of death by an authorized transferee), provided that this option shall be exercisable only to the extent that this option was
exercisable by the Participant on the date of his or her death or disability, and further provided that this option shall not be exercisable after the Final Exercise Date. 

        (e)    Discharge for Cause.    If the Participant, prior to the Final Exercise Date, is
discharged by the Company for "cause" (as defined below), the right to exercise this option shall terminate immediately upon the effective date of such discharge. "Cause" shall mean willful misconduct
by the Participant or willful failure by the Participant to perform his or her responsibilities to the Company (including, without limitation, breach by the Participant of any provision of any
employment, consulting, advisory, nondisclosure, non-competition or other similar agreement between the Participant and the Company), as determined by the Company, which determination
shall be conclusive. The Participant shall be considered to have been discharged for "Cause" if the Company determines, within 30 days after the Participant's resignation, that discharge for
cause was warranted. 

4.     Tax Matters. 

        (a)    Withholding.    No Shares will be issued pursuant to the exercise of this option
unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in
respect of this option. 

        (b)    Disqualifying Disposition.    If the Participant disposes of Shares acquired upon
exercise of this option within two years from the Grant Date or one year after such Shares were acquired pursuant to exercise of this option, the Participant shall notify the Company in writing of
such disposition. 

5.     Nontransferability of Option. 

        This
option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent
and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant. 

6.     Provisions of the Plan. 

        This
option is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this option. 

        IN
WITNESS WHEREOF, the Company has caused this option to be executed under its corporate seal by its duly authorized officer. This option shall take effect as a sealed instrument. 

	 	 	MOMENTA PHARMACEUTICALS, INC.
	

Dated:	
 	

By:	

 
	 	 	 	

	

 	
 	

Name:	

 
	 	 	 	

	 	 	Title:	 
	 	 	 	

PARTICIPANT'S ACCEPTANCE 

        The
undersigned hereby accepts the foregoing option and agrees to the terms and conditions thereof. The undersigned hereby acknowledges receipt of a copy of the Company's 2004 Stock
Incentive Plan. 

	 	 	PARTICIPANT:
	

 	
 	

	

 	
 	

Address:	

 
	 	 	 	

	

 	
 	

 	

EXHIBIT A

NOTICE OF STOCK OPTION EXERCISE 

Date:  

Participant
name and address: 

Attention:
Treasurer 

Dear
Sir or Madam: 

        I
am the holder of an Incentive Stock Option granted to me under the Momenta Pharmaceuticals, Inc. (the "Company") 2004 Stock Incentive Plan on
                for the purchase of                  shares of Common Stock
of the Company at a purchase price of
$                 per share. 

        I
hereby exercise my option to purchase                  shares of Common Stock (the "Shares"), for which I have enclosed
                 in the amount of $                . Please register my
stock certificate as follows: 

	 	 	 	 	(check applicable box)
	

Name(s):	
 	

	
 	

o	
 	

TEN COM
	

 	
 	

	
 	

o	
 	

TEN ENT
	

Address:	
 	

	
 	

o	
 	

JT TEN
	

Tax I.D. #:	
 	

	
 	

o	
 	

UNIF GIFT MIN ACT

        I
represent, warrant and covenant as follows: 

        1.     I
am purchasing the Shares for my own account for investment only, and not with a view to, or for sale in connection with, any distribution of the Shares in violation of
the Securities Act of 1933 (the "Securities Act"), or any rule or regulation under the Securities Act. 

        2.     I
have had such opportunity as I have deemed adequate to obtain from representatives of the Company such information as is necessary to permit me to evaluate the merits
and risks of my investment in the Company. 

        3.     I
have sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of the Shares and to make an informed
investment decision with respect to such purchase. 

        4.     I
can afford a complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite period. 

        5.     I
understand that (i) the Shares have not been registered under the Securities Act and are "restricted securities" within the meaning of Rule 144 under the
Securities Act, (ii) the Shares cannot be sold, transferred or otherwise disposed of unless they are subsequently registered under the Securities Act or an exemption from registration is then
available; (iii) in any event, the exemption from registration under Rule 144 will not be available for at least one year and even then will not be available unless a public market then
exists for the Common Stock, adequate information concerning the Company is then available to the public, and other terms and conditions of Rule 144 are complied with; and (iv) there is
now no registration statement on file with the Securities and Exchange Commission with respect to any stock of the Company and the Company has no obligation or current intention to register the Shares
under the Securities Act. 

Very
truly yours, 

(Signature) 

QuickLinks

Exhibit 10.1

Momenta Pharmaceuticals, Inc. Incentive Stock Option Agreement Granted Under 2004 Stock Incentive Plan

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]